A Phase I, randomized, double-blind, multi-centre, placebo-controlled, dose-escalation study to evaluate the safety, reactogenicity and immunogenicity of AstriVax’ investigational vaccine for the prevention of yellow fever (AVX70120), and of AstriVax’ investigational vaccine for the prevention of rabies (AVX70481), in healthy adults aged 18 to 40 years.

2024-511194-29-00 Protocol AVX1248-101 Human pharmacology (Phase I) - First administration to humans Ended

Start 16 Jun 2024 · End 26 Jan 2026 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol AVX1248-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 144
Countries 1
Sites 2

Yellow fever

Key facts

Sponsor
AstriVax
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
16 Jun 2024 → 26 Jan 2026
Decision date (initial)
2024-06-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Yellow fever

VersionLevelCodeTermSystem organ class
20.0 PT 10037742 Rabies 100000004862
20.0 PT 10048240 Yellow fever 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstriVax

Sponsor organisation
AstriVax
Address
Ambachtenlaan 1
City
Leuven
Postcode
3001
Country
Belgium

Scientific contact point

Organisation
AstriVax
Contact name
Mathieu Peeters

Public contact point

Organisation
AstriVax
Contact name
Hanne Callewaert

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 144 2
Rest of world 0

Investigational sites

Belgium

2 sites · Ended
University Of Antwerp
Centre for Evaluation of Vaccination (CEV), Drie Eikenstraat 663, 2650, Edegem
Universitair Ziekenhuis Gent
Center for Vaccinology (CEVAC), Corneel Heymanslaan 10, 9000, Gent

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-06-16 2026-01-26 2024-06-16 2026-01-26

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-15 Belgium Acceptable
2024-06-13
2024-06-13
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-19 Belgium Acceptable
2024-07-16
2024-07-16
3 SUBSTANTIAL MODIFICATION SM-2 2024-07-18 Belgium Acceptable 2024-08-12
4 SUBSTANTIAL MODIFICATION SM-3 2024-09-13 Belgium Acceptable
2024-11-07
2024-11-07
5 SUBSTANTIAL MODIFICATION SM-4 2025-03-13 Belgium Acceptable
2025-04-23
2025-04-23